Understanding the Negative Effects of Bed Rest and Using Exercise as Countermeasure

Microgravity Research Analogue (MRA): Understanding the Health Impact of Inactivity for the Benefit of Older Adults and Astronauts Initiative

Physical activity appears to be an important lifestyle habit to achieve healthy aging by promoting autonomy and quality of life. Interestingly, the dramatic changes that the human body undergoes due to bedrest for illnesses and hospitalization are similar to those seen over decades of normal aging. Bedrest in otherwise healthy older individuals can lead to a reduction of muscle size and strength, changes in bone strength and function of the heart and blood vessels. Bedrest can also lead to changes in keeping proper balance as well as changes in processing and understanding information. All of these factors negatively affect activities of daily living leading to physical function impairment and development of frailty, a clinical condition associated with an increased risk for disease and death.

The purpose of this study is to investigate whether exercise can counteract the negative effects of 2-week head tilt down bed rest on muscle function and metabolism, postural control, bone structure, orthostatic tolerance and cognitive function in adults.

For this study the investigators will recruit 24 healthy men and women between 55 - 65 years of age. All subjects will spend a total of 26 days (5 days of adaption period, 14 days of bed rest with 6 degrees of downward inclination, and 7 days of recovery period) at the McGill University Health Centre (MUHC). During this study, 12 subjects will randomly undergo an exercise intervention as countermeasure during the 14 days of bed rest period and 12 will serve as control.

Each subjects participation in this study will involve 1 telephone call (pre-screening) and 4 visits at the MUHC: 1 screening visit (Visit 1) followed by a 26-day long visit (Visit 2) and 2 follow-up visits (Visit 3 and Visit 4). During Visits 2 - 4 various measurements will be performed to assess sensorimotor control, muscle function and metabolism, bone structure, cardiovascular function, cognitive performance and function, and specimen collection (blood, urine, saliva, feces and muscle tissue).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Quebec
      • Montréal, Quebec, Canada, H4A 3J1
        • Recruiting
        • Royal Victoria Hospital - Glen site
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • A minimum of 20 and a maximum of 24 non-smoking participants in the age group of 55 to 65 years old, half male and half female.
  • Female participants must be menopausal (no menses for at least 1 year (or documented ovariectomy) and a serum FSH above 30 IU/L).
  • Height between 158 to 190 cm with a body mass index between 20 to 30 kg/m2.
  • Physically and mentally healthy subjects that will have successfully passed the psychological and medical screening appropriate for the age group.
  • Participation in at least 2.5 hours of exercise at a moderate to vigorous-intensity aerobic activity per week.
  • Willing to be assigned randomly either to the exercise or the control group.

Exclusion Criteria:

  • Participants must be dementia-free, drug- or alcohol-addiction free, with no history of heart attacks, no thrombosis risk, no severe allergies, no hypocalcaemia, no uric acidemia, no orthostatic intolerance, no vestibular disorders, no considerable musculoskeletal issues, no chronic back pain, no head trauma, no seizures, no ulcers, no renal stones, no gastro-esophageal reflux disease or renal function disorder, no hiatus hernia, no migraines, and no mental illness.
  • Electrocardiogram abnormalities
  • Anemia
  • Low bone mineral density
  • Medication requirements that may interfere with the interpretation of the results
  • Recent substandard nutritional status
  • Claustrophobia
  • Special dietary requests (e.g. vegetarian, vegan or some other diet)
  • Sedentary people and people that are addicted to exercise
  • Metallic implants (pacemakers, ICDs, CRT devices, infusion pumps, cerebral artery aneurysm clips, dental implants, tissue expander etc.), osteosynthesis material
  • Given blood in the past 3 months before the onset of the experiment
  • Smoked (tobacco and/or marijuana (THC)) within 6 months prior to the start of the study
  • Abused drugs, medicine or alcohol within up to 30 days prior to the start of the study
  • Participated in another study within 2 months before study onset

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exercise
Participants will perform aerobic and strength exercises for 2 weeks.
Participants will undergo an exercise program during the 2-week bed rest period.
No Intervention: No exercise
Participants will not perform any exercises.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in cognition status of participants with head down bed rest (HDBR) with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
NIH Toolbox Cognition Battery (computerized)
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in cognition status of participants with head down bed rest (HDBR) with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
CLSA cognition questionnaire
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in emotional status of participants with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods

Positive and Negative Affect Scale

- For both scales scores can range from 10-50, with higher scores representing higher levels of positive or negative affect.

Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in emotional status of participants with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods

General Health Questionnaire (GHQ-28).

  • Using Likert 4-point scale with the min score being 0 and max score being 84.
  • Higher scores indicate a higher level of distress.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in brain structure with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Assessment of brain anatomy using a MRI.
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in brain function with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Measurement of neuronal, cerebrovascular, and connectivity integrity with functional MRI.
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in muscle muscle mass with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Body MRI
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in muscle fat infiltration with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Body MRI
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in adiposity with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Body MRI
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in ventricular volume of the heart with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Using a heart MRI left and right ventricular volumes will be assessed.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in ventricular mass with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Using a heart MRI left and right ventricular mass will be assessed.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in bone structure with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
High resolution peripheral quantitative computed tomography (HR-pQCT)
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in muscle strength with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Quantitative Muscle Dynamometry (Biodex)
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in muscle strength with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Vertical jump
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in muscle-pump baroreflex with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Supine-to-stand test
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in balance control with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Postural equilibrium control test
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in orthostatic tolerance with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Tilt test
Throughout the 26-day study period: at Baseline and Recovery periods
Cardiac and vascular changes with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Using high frame rate ultrasound (HiFRUS) arterial wall shear stress will be assessed.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Cardiac and vascular changes with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Using high frame rate ultrasound (HiFRUS) arterial wall stiffness will be assessed.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Cardiac and vascular changes with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Using high frame rate ultrasound (HiFRUS) cardiac mass will be assessed.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Cardiac and vascular changes with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Using high frame rate ultrasound (HiFRUS) patterns of blood flow will be assessed.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in Fractional Synthesis Rate (FSR) with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: during HDBR period
Measurement of protein turnover.
Throughout the 26-day study period: during HDBR period
Changes in sleep quality with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Sleep quality will be assessed using a 3-electrode electroencephalogram (EEG) Sleep Profiler and a wrist worn actigraphy.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in sleep architecture with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Using 3-electrode electroencephalogram (EEG) Sleep Profiler electrical patterns of brain activity will be measured in order to assess sleep cycles and sleep stages.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in frailty status with HDBR with and without exercise countermeasure.
Time Frame: Throughput the 26-day study period: at Baseline, HDBR and Recovery periods
CLSA-FI questionnaire
Throughput the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in the gut microbiome with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
To assess gut microbiome, stool samples will be collected and targeted sequencing of the variable regions 4 and 5 (V4-V5) of the 16S ribosomal RNA gene will be performed on an Illumina MiSeq.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in the constitution of the oral microbiome with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
To assess oral microbiome, saliva samples will be collected and targeted sequencing of the variable regions 4 and 5 (V4-V5) of the 16S ribosomal RNA gene will be performed on an Illumina MiSeq.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in physical performance with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Short Physical Performance Battery test
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in physical performance with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Timed-up-and-Go test
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in dynamic balance with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Four-square step test
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in bone markers with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods

The following bone markers will be assessed using ELISA kits:

  • Total osteocalcin
  • Undercarboxylated osteocalcin
  • Sclerostin
  • NTX (N-terminal Telopeptide)
  • CTX (C-terminal telopeptide)
  • Bone Specific Alkaline Phosphatase (BSAP)
  • Procollagen type 1 amino-terminal propeptide (P1NP)
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in growth factors with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods

The following growth factors will be measured with Multiplex:

  • Basic fibroblast growth factor
  • Granulocyte colony-stimulating factor (G-CSF)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF)
  • Platelet-derived growth factor BB (PDGF-BB)
  • Transforming growth factor β (TGF-β)
  • Vascular endothelial growth factor (VEGF)
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in cytokines with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods

The following cytokines will be measured with Multiplex:

  • Eotaxin
  • Interferon gamma (IFN-γ)
  • IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17
  • Tumour necrosis factor (TNF-α)
  • Interferon gamma- induced protein 10 (IP-10)
  • Monocyte chemoattractant protein 1 (MCP-1)
  • Macrophage inflammatory protein-1α (MIP-1α)
  • Macrophage inflammatory protein-1β (MIP-1β)
Throughout the 26-day study period: at Baseline and Recovery periods

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in neuromotor function with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Neuromuscular activity will be assessed using electromyography.
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in aerobic capacity with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Bicycle Ergometer Test
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in body composition with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline and Recovery periods
Lean muscle and fat mass will be assess using dual energy X-ray absorptiometry.
Throughout the 26-day study period: at Baseline and Recovery periods
Changes in insulin sensitivity with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Will measure excursion curves of glucose and insulin.
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods
Changes in neuronal factors with HDBR with and without exercise countermeasure.
Time Frame: Throughout the 26-day study period: at Baseline, HDBR and Recovery periods

The following bone markers will be assessed using ELISA kits:

  • Neurofilament light chain
  • Glial fibrillary acidic protein
  • Myelin basic protein
  • Total tau
  • Aβ1-40
  • Aβ1-42
  • BDNF
Throughout the 26-day study period: at Baseline, HDBR and Recovery periods

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: José A. Morais, MD, McGill University Health Centre/Research Institute of the McGill University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 12, 2021

Primary Completion (Anticipated)

February 1, 2022

Study Completion (Anticipated)

April 1, 2022

Study Registration Dates

First Submitted

May 6, 2021

First Submitted That Met QC Criteria

July 6, 2021

First Posted (Actual)

July 16, 2021

Study Record Updates

Last Update Posted (Actual)

September 5, 2021

Last Update Submitted That Met QC Criteria

September 2, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • MP-37-2021-7170

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe